^
    Back
    Association details:
    Biomarker:CD74-ROS1 rearrangement + ROS1 F2004V + ROS1 L2086F
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) +
    Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    NPJ Precis Oncol
    Title:

    Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance

    Published date:
    06/08/2023
    Excerpt:
    We present a case of a patient with metastatic ROS1-rearranged NSCLC with dual ROS1 F2004V and L2086F resistance mutations who radiographically responded to the combination of lorlatinib and cabozantinib in a patient with metastatic NSCLC.
    DOI:
    https://doi.org/10.1038/s41698-023-00381-0